Neuroblastoma

News alerts, weekly reports and conference planners

Related cancers:

‹

CNS Tumor (533)

Brain Cancer (525)

Glioma (484)

Pituitary Gland Carcinoma (10)

Pituitary Gland Carcinoma (10)

Meningioma (8)

›

ALK R1275Q	Neuroblastoma	ALK R1275Q	Neuroblastoma	lorlatinib Sensitive: C4 – Case Studies Nat Commun - 3 weeks (New C4) lorlatinib Sensitive : C4 Nat Commun - 3wk	lorlatinib Sensitive: C4 – Case Studies Nat Commun - 3 weeks lorlatinib Sensitive : C4 Nat Commun - 3 weeks - (New C4)
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	dinutuximab beta Sensitive: A1 - Approval dinutuximab beta Sensitive : A1	dinutuximab beta Sensitive: A1 - Approval dinutuximab beta Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	melphalan Sensitive: A1 - Approval melphalan Sensitive : A1	melphalan Sensitive: A1 - Approval melphalan Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	dinutuximab Sensitive: A1 - Approval dinutuximab Sensitive : A1	dinutuximab Sensitive: A1 - Approval dinutuximab Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1	cyclophosphamide Sensitive: A1 - Approval cyclophosphamide Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	naxitamab Sensitive: A1 - Approval naxitamab Sensitive : A1	naxitamab Sensitive: A1 - Approval naxitamab Sensitive : A1
ALK positive	Neuroblastoma	ALK positive	Neuroblastoma	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1
ALK positive	Neuroblastoma	ALK positive	Neuroblastoma	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
ALK R1275Q	Neuroblastoma	ALK R1275Q	Neuroblastoma	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
ATRX mutation	Neuroblastoma	ATRX mutation	Neuroblastoma	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
ALK rearrangement + ALK R1275Q + TP53 mutation	Neuroblastoma	ALK rearrangement + ALK R1275Q + TP53 mutation	Neuroblastoma	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4
PGBD5 overexpression	Neuroblastoma	PGBD5 overexpression	Neuroblastoma	cisplatin Sensitive: D – Preclinical cisplatin Sensitive : D	cisplatin Sensitive: D – Preclinical cisplatin Sensitive : D
PGBD5 overexpression	Neuroblastoma	PGBD5 overexpression	Neuroblastoma	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D
PGBD5 underexpression	Neuroblastoma	PGBD5 underexpression	Neuroblastoma	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D
ALK R1275Q	Neuroblastoma	ALK R1275Q	Neuroblastoma	TAE-684 Resistant: D – Preclinical TAE-684 Resistant : D	TAE-684 Resistant: D – Preclinical TAE-684 Resistant : D
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	panobinostat + GSK2816126 Sensitive: D – Preclinical panobinostat + GSK2816126 Sensitive : D	panobinostat + GSK2816126 Sensitive: D – Preclinical panobinostat + GSK2816126 Sensitive : D
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	JQ-1 + panobinostat Sensitive: D – Preclinical JQ-1 + panobinostat Sensitive : D	JQ-1 + panobinostat Sensitive: D – Preclinical JQ-1 + panobinostat Sensitive : D
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	brigatinib Resistant: D – Preclinical brigatinib Resistant : D	brigatinib Resistant: D – Preclinical brigatinib Resistant : D
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	crizotinib Resistant: D – Preclinical crizotinib Resistant : D	crizotinib Resistant: D – Preclinical crizotinib Resistant : D
ALK F1174L	Neuroblastoma	ALK F1174L	Neuroblastoma	crizotinib Resistant: D – Preclinical crizotinib Resistant : D	crizotinib Resistant: D – Preclinical crizotinib Resistant : D
ALK F1174L	Neuroblastoma	ALK F1174L	Neuroblastoma	AZD3463 Sensitive: D – Preclinical AZD3463 Sensitive : D	AZD3463 Sensitive: D – Preclinical AZD3463 Sensitive : D
ALK F1174L	Neuroblastoma	ALK F1174L	Neuroblastoma	alectinib Sensitive: D – Preclinical alectinib Sensitive : D	alectinib Sensitive: D – Preclinical alectinib Sensitive : D
ALK amplification	Neuroblastoma	ALK amplification	Neuroblastoma	alectinib Sensitive: D – Preclinical alectinib Sensitive : D	alectinib Sensitive: D – Preclinical alectinib Sensitive : D
ALK F1245C	Neuroblastoma	ALK F1245C	Neuroblastoma	lorlatinib Sensitive: D – Preclinical lorlatinib Sensitive : D	lorlatinib Sensitive: D – Preclinical lorlatinib Sensitive : D
ALK F1174C	Neuroblastoma	ALK F1174C	Neuroblastoma	lorlatinib Sensitive: D – Preclinical lorlatinib Sensitive : D	lorlatinib Sensitive: D – Preclinical lorlatinib Sensitive : D
ALK F1174L	Neuroblastoma	ALK F1174L	Neuroblastoma	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D	TAE-684 Sensitive: D – Preclinical TAE-684 Sensitive : D
MYCN amplification + ALK rearrangement	Neuroblastoma	MYCN amplification + ALK rearrangement	Neuroblastoma	brigatinib Sensitive: D – Preclinical brigatinib Sensitive : D	brigatinib Sensitive: D – Preclinical brigatinib Sensitive : D
MYCN amplification + ALK F1174V	Neuroblastoma	MYCN amplification + ALK F1174V	Neuroblastoma	brigatinib Sensitive: D – Preclinical brigatinib Sensitive : D	brigatinib Sensitive: D – Preclinical brigatinib Sensitive : D
MYCN amplification + ALK F1174V	Neuroblastoma	MYCN amplification + ALK F1174V	Neuroblastoma	crizotinib Sensitive: D – Preclinical crizotinib Sensitive : D	crizotinib Sensitive: D – Preclinical crizotinib Sensitive : D
NF1 underexpression	Neuroblastoma	NF1 underexpression	Neuroblastoma	binimetinib Sensitive: D – Preclinical binimetinib Sensitive : D	binimetinib Sensitive: D – Preclinical binimetinib Sensitive : D
MYCN amplification + ALK F1174L	Neuroblastoma	MYCN amplification + ALK F1174L	Neuroblastoma	lorlatinib Sensitive: D – Preclinical lorlatinib Sensitive : D	lorlatinib Sensitive: D – Preclinical lorlatinib Sensitive : D

Neuroblastoma

Associations(48)

Associations
(48)